IRIX Iridex Corp.

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024

MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release financial results for the fourth quarter and full year 2023 and provide an update on its strategic review process after the close of trading on Tuesday, March 26, 2024.

The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at: .

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at .

MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.

Investor Relations Contact:

Philip Taylor

Gilmartin Group



EN
20/03/2024

Underlying

IRIXIridex Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iridex Corp.

 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

Iridex Reports Fourth Quarter and Full Year 2023 Financial Results Advances strategic review to unlock shareholder value MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent Highlights Generated total reve...

March 26, 2024 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results a...

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024 MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release financial results for the fourth quarter and full year 2023 and provide an update on its strategic review process after the close of trading on Tuesday, March 26, 2024. ...

March 20, 2024 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Corporation Receives European Patent on MicroPulse Technology

Iridex Corporation Receives European Patent on MicroPulse Technology The Advanced Short Pulse Laser System MOUNTAIN VIEW, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use”. This groundbreaking patent further protects Iridex’s intellectual property enc...

February 6, 2024 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical ...

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex’ Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership e...

January 24, 2024 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Ma...

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma MOUNTAIN VIEW, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next-generation platform Iridex 532® and Iridex 577® Lasers alongside its 35th anniversary celebration. The announcement was made ahead of their official showcase at the Hawaiian Eye and Retina 2024 Meeting from January 13-19, 2024. Both la...

January 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch